About Poly(A) RNA polymerase GLD2
Poly(A) RNA polymerase GLD2 (TENT2) is a protein
from Homo sapiens identified by UniProt accession
Q6PIY7, 484 residues long.
MolForge cross-references it against 0 known binders and
26 disease associations.
Target properties
| Protein name | Poly(A) RNA polymerase GLD2 |
| UniProt accession | Q6PIY7 |
| Gene | TENT2 |
| Organism | Homo sapiens |
| Length | 484 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (26)
Diseases linked to this target (Open Targets).
- body height · score 0.28
- appendicular lean mass · score 0.17
- neoplasm · score 0.08
- hepatocellular carcinoma · score 0.03
- diet measurement · score 0.02
- bipolar disorder · score 0.02
- attention deficit hyperactivity disorder · score 0.02
- juvenile dermatomyositis · score 0.01
- hepatitis C virus infection · score 0.01
- nonpapillary renal cell carcinoma · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6PIY7-F1 | alphafold | PREDICTED | 76.70 | — |
Amino-acid sequence (484 residues)
MFPNSILGRP PFTPNHQQHN NFFTLSPTVY SHQQLIDAQF NFQNADLSRA VSLQQLTYGN VSPIQTSASP LFRGRKRLSD EKNLPLDGKR QRFHSPHQEP TVVNQIVPLS GERRYSMPPL FHTHYVPDIV RCVPPFREIA FLEPREITLP EAKDKLSQQI LELFETCQQQ ISDLKKKELC RTQLQREIQL LFPQSRLFLV GSSLNGFGTR SSDGDLCLVV KEEPCFFQVN QKTEARHILT LVHKHFCTRL SGYIERPQLI RAKVPIVKFR DKVSCVEFDL NVNNIVGIRN TFLLRTYAYL ENRVRPLVLV IKKWASHHQI NDASRGTLSS YSLVLMVLHY LQTLPEPILP SLQKIYPESF SPAIQLHLVH QAPCNVPPYL SKNESNLGDL LLGFLKYYAT EFDWNSQMIS VREAKAIPRP DGIEWRNKYI CVEEPFDGTN TARAVHEKQK FDMIKDQFLK SWHRLKNKRD LNSILPVRAA VLKR
Explore Poly(A) RNA polymerase GLD2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets